These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28393006)

  • 21. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report.
    Fang L; He J; Xia J; Dong L; Zhang X; Chai Y; Li Y; Niu M; Hang T; Li S
    Oncol Lett; 2017 Jul; 14(1):593-598. PubMed ID: 28693210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrence of nivolumab-induced interstitial lung disease and cancer invasion.
    Kanai O; Nakatani K; Fujita K; Okamura M; Mio T
    Respirol Case Rep; 2017 Nov; 5(6):e00257. PubMed ID: 28811904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.
    Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C
    J Immunother Cancer; 2019 Oct; 7(1):281. PubMed ID: 31672171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor Lysis Syndrome following a Single Dose of Nivolumab for Relapsed Small-Cell Lung Cancer.
    Hayes SM; Wiese C; Schneidewend R
    Case Rep Oncol; 2021; 14(3):1652-1659. PubMed ID: 35082621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential CT Findings in Patients With Non-small-cell Lung Cancer Receiving Nivolumab.
    Johnson DY; Short RG; Patz EF
    Clin Lung Cancer; 2018 Mar; 19(2):175-180. PubMed ID: 29153896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice.
    Bruera G; Giuliani A; Romano L; Chiominto A; Di Sibio A; Mastropietro S; Cosenza P; Ricevuto E; Schietroma M; Carlei F;
    BMC Cancer; 2019 Oct; 19(1):960. PubMed ID: 31619203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nivolumab Therapy for Synchronous
    Yamasaki M; Saito N; Hada Y; Miyamoto S; Okanobu H; Ikeda N; Daido W; Ishiyama S; Deguchi N; Taniwaki M; Ohashi N
    Case Rep Oncol; 2017; 10(1):361-367. PubMed ID: 28559820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report.
    Ma S; He Z; Fu H; Wang L; Wu X; Zhang Z; Wang Q
    Transl Lung Cancer Res; 2020 Feb; 9(1):139-143. PubMed ID: 32206560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases.
    Ahn S; Hwang SH; Han J; Choi YL; Lee SH; Ahn JS; Park K; Ahn MJ; Park WY
    J Pathol Transl Med; 2016 Jul; 50(4):258-63. PubMed ID: 27160687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case report: Emerging therapies for transformed small cell lung cancer: efficacy of serplulimab and a comprehensive case report.
    Lyu HX; Ma WH; Zhang YQ; Jin H; Wang YD; Zhao M
    Front Med (Lausanne); 2024; 11():1406515. PubMed ID: 39386753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spontaneous remission of advanced progressive poorly differentiated non-small cell lung cancer: a case report and review of literature.
    Yoon HY; Park HS; Cho MS; Shim SS; Kim Y; Lee JH
    BMC Pulm Med; 2019 Nov; 19(1):210. PubMed ID: 31711463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer.
    Bar J; Ofek E; Barshack I; Gottfried T; Zadok O; Kamer I; Urban D; Perelman M; Onn A
    Lung Cancer; 2019 Dec; 138():109-115. PubMed ID: 31683093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan.
    Guan J; Chen M; Xiao N; Li L; Zhang Y; Li Q; Yang M; Liu L; Chen L
    Med Oncol; 2016 Jan; 33(1):1. PubMed ID: 26589606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer.
    Tamura N; Horinouchi H; Sekine K; Matsumoto Y; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Ohe Y
    Thorac Cancer; 2019 May; 10(5):1141-1148. PubMed ID: 30913364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis.
    Cavanna L; Citterio C; Orlandi E
    Oncotarget; 2019 Jan; 10(2):209-215. PubMed ID: 30719215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer.
    de Jong C; Peters BJM; Schramel FMNH
    Chemotherapy; 2018; 63(5):272-277. PubMed ID: 30572331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor.
    Kim WJ; Kim S; Choi H; Chang J; Shin HJ; Park CK; Oh IJ; Kim KS; Kim YC; Choi YD
    Thorac Cancer; 2015 Nov; 6(6):800-4. PubMed ID: 26557922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.